Background Eosinophilic inflammation, which may be a consequence of interleukin-5 action,
is a characteristic feature of some forms of asthma. However, in three previous clinical trials …

Background Many patients with severe asthma rely on oral glucocorticoids to manage their
disease. We investigated whether benralizumab, a monoclonal antibody directed against the …

Background Asthma is a chronic condition in which sufferers may have occasional or frequent
exacerbations resulting in visits to the emergency department (ED). Aminophylline has …

Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

Rationale: Eosinophilic asthma is a phenotype of asthma characterized by the persistence
of eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils. …

Background In patients with severe eosinophilic asthma, local maturation rather than systemic
recruitment of mature cells might contribute to persistent airway eosinophilia. Group 2 …

Patients with severe uncontrolled asthma have disproportionally high morbidity and healthcare
utilization as compared with their peers with well-controlled disease. Although treatment …

Background Asthma is a respiratory (airway) condition that affects an estimated 300 million
people worldwide and is associated with significant morbidity and mortality. Omalizumab is a …

Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual
patient disease triggers and response to therapy. Several asthma phenotypes have now …